maintain biogen fair valu estim assum
probabl aducanumab launch
updat forecast estim may
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research apr
estim may
price data may
rate updat may
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
think specialty-market-focus drug portfolio
strategi root merger
multipl sclerosi drug avonex idec cancer drug rituxan
rituxan market penetr high patent unit
state deriv profit share roch expir
lead biosimilar approv late
pressur profit share subcutan rituxan
well novel antibodi gazyva allow extend oncolog
ms avonex longer-act plegridi gener billion
annual sale remain lead ms interferon drug biogen
also acquir full right ms antibodi tysabri
billion annual sale partner oral ms drug tecfidera
billion annual strong launch continu show
solid safeti efficaci data recent patent rule
valid formul patent abil
new oral drug vumer improv gi toler
partli off-set headwind increas competit ms
market price power demand inject
ms portfolio erod face new competit biogen
receiv substanti royalti biggest new competitor
roch ocrevu help off-set pressur older ms drug
outsid ms strong human genet valid
partner ioni billion franchis although competit
novarti gene therapi zolgensma approv may
roch oral drug risdiplam could begin erod spinraza sale
aducanumab largest potenti could launch
first disease-modifi alzheim therapi late
signific uncertainti surround potenti approv
aducanumab think market also underestim
remain pipelin includ continu partnership
ioni drug candid treat condit includ stroke
parkinson pain al
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
idec merg combin forc market
multipl sclerosi drug avonex idec cancer drug rituxan today
rituxan next-gener antibodi gazyva market via
collabor roch also market novel ms drug plegridi
tysabri tecfidera vumer japan ms portfolio
co-promot eisai hemophilia therapi eloct alprolix partner
sobi spun part bioverativ sever
drug candid phase trial neurolog neurodegen
diseas launch spinraza partner ioni
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
maintain biogen fair valu estim
assum probabl aducanumab launch
maintain fair valu estim biogen
result despit
expect sale pressur later year well
delay fda file alzheim diseas drug
candid aducanumab push back earli
third-quart saw top-lin growth
billion first quarter exclud
headwind revenu weak comparison due
larg hemophilia inventori sale first quarter
saw product sale growth driven growth
firm multipl sclerosi ms franchis patient
growth sale growth spinal muscular atrophi drug
spinraza growth biosimilar sale europ
pandem appear acceler sale
first quarter benefit sale ms therapi
particularli europ slightli benefit spinraza
continu model sale declin full year result
delay use ms treatment like tysabri ocrevu
delay treatment spinraza biosimilar
competit oncolog therapi rituxan unlik biogen
interferon therapi tecfidera ms
therapi requir go doctor offic hospit
receiv treatment although note tri
facilit home infus tysabri aducanumab
could eventu infus home long term
despit clinic trial delay includ stroke drug
requir hospit administr
expect see vast major remain near-
term readout end roughli line prior
guidanc overal despit coronaviru pressur
therapi delay aducanumab continu see
moat share look under-valued
dive deeper aducanumab began global re-
dose studi drug march patient
prior discontinu studi firm delay file
fda manag expect complet
applic third quarter manag note
focus less speed file qualiti
allow time full analysi complex dataset up-front
rather risk back forth fda file
later delay manag also note pandem
factor delay particularli due staffer
unnam execut sick past
coupl month make chang
aducanumab sale estim alreadi push
expect launch model due concern
surround new product launch pandem
pleas see coronaviru updat shutdown relax
pipelin advanc detail broader analysi
pandem detail inform
analysi brand drug firm impact coronaviru
pleas see april report coronaviru caus limit
impact pharma
tecfidera maintain estim
remain bullish firm abil defend key patent
discuss feb note patent trial
appeal board rule favor valid key
patent multipl sclerosi drug tecfidera offer
support formul patent protect tecfidera
expect district court decis
two patent infring case would-b gener
competitor later year think ptab decis
februari support case continu model
mild tecfidera declin due brand competit
yesterday appeal court decis
uphold district court decis bafiertam
infring biogen tecfidera patent could allow
launch drug substitut
manag see signific
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
ocrevu sale hit nearli billion assum
gener tecfidera off-set
total fumar revenu launch vumer
alzheim assum probabl approv
aducanumab late amount nearli
aducanumab includ alzheim relat sale
tau pipelin
probability-adjust sale
spinraza nusinersen assum sale begin declin
new patient treat spinraza patient could
opt either compet gene therapi novarti zolgensma
small-molecul therapi roche/ptc risdiplam
fewer patient initi therapi first year therapi
twice expens
overal think top line grow annual
bottom-lin growth includ
placehold futur litig risk roughli
rest brand drug industri
still rate systemat risk surround share
averag use cost equiti
assumpt align capit cost assumpt
return equiti investor like demand
rel
inelast portfolio ms
high-risk natur pipelin target
base-cas scenario expect tecfidera/vumer
sale fall around billion also assum
flat tysabri sale around billion annual
scenario think oper margin remain
lower fair valu estim
account coronavirus-rel
treatment delay hospit administ therapi
spinraza well delay clinic trial novel
read could still track parkinson ms
ophthalmolog gene therapi among al
stroke trial expect data could
delay sever month overal lower
sale estim million sale howev
aducanumab fda file expect day
think potenti aducanumab launch late earli
risk signific delay point also
ms therapi like oral tecfidera inject
avonex/plegridi deliv home
see disrupt also think delay neurolog infus
center therapi could less pronounc tysabri
ocrevu infus
think combin global sale avonex plegridi
continu fall high-single-digit declin annual
new competit expect tysabri stay
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
bull-cas scenario -- valu per
share -- assum tecfidera vumer remain
domin player ms market allow secur
continu sale billion annual assum
physician see vumer gi benefit tecfidera
signific also assum probabl
aducanumab approv scenario bear-cas
scenario valu per share forecast
minim sale tecfidera/vumer
assum tecfidera headwind brand competitor
perceiv insignific gi benefit vumer
includ sale aducanumab bear-cas scenario
final bear-cas scenario also incorpor hit
 sale beyond potenti disrupt
achiev strong profit base roch
collabor oncolog diversifi ms
franchis think barrier entri high potenti
biosimilar product strong
 strategi maintain leadership ms
neurodegen diseas price power strong
patient need novel therapi high
build solid pipelin factor contribut
firm wide moat return invest capit
think averag high teen
explicit forecast period easili exceed estim
cost capit
profit share roch pois see growth
rituxan remain standard care sever form
hematolog cancer profit share rituxan
erod biosimilar competit
gazyva superior data leukemia certain form
lymphoma well potenti lupu help counter
threat profit share addit receiv
substanti royalti roch ms
therapi ocrevu model peak sale
roughli billion billion domin
turn ms franchis avonex lead
interferon therapi ms long-term safeti
record rel conveni once-weekli inject
plegridi improv conveni twice-monthli
achiev
blockbust sale base outstand efficaci despit
rare seriou side effect think effort target
drug patient least like experi side effect
allow firm see continu sale despit novel
product cleaner safeti profil oral ms drug
tecfidera strong launch continu show solid
safeti efficaci data drug appear
emerg patent litig risk protect
 abil new oral drug
vumer improv gi toler partli off-set
headwind competit still assum
total oral ms drug sale declin
except tecfidera current
blockbust biolog biosimilar competit
loom threat think signific manufactur
develop cost biosimilar maker expect
incur would slow eros sale product
limit number contend abil
compet price data qualiti may also issu
biosimilar first applic avonex biosimilar
reject base insuffici efficaci
ms biosimilar radar oncolog delay
discontinu rituxan biosimilar push
european launch launch began late
tysabri like lower-prior target
biosimilar entrant given risk monitor potenti
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
seriou side effect certain patient
see moat trend stabl think
introduct new product firm grow
late-stag pipelin off-set new competit
competit price pressur ms oncolog
increas think strong efficaci oral ms therapi
biogen tecfidera novarti gilenya inject
therapi roch launch ocrevu make
less like new patient start older inject
avonex tysabri addit payer
leverag price negoti assum
abl take avonex price increas
roughli annual net basi past sever
year assum
signific abil rais net price futur biogen
recent launch conveni interferon therapi
plegridi littl chang trend opinion
model high-single-digit declin combin
efficaci allow maintain flat sale despit new
competit addit report revenu
matur biosimilar
competit launch
howev think pipelin off-set
pressur older drug roch receiv food drug
administr approv novel effect antibodi
therapi ocrevu relaps ms
compet primari progress ms
approv treatment littl off-label use
current drug add competit
landscap also benefit due
royalti sale two third global
billion ms market exposur new ppm
indic biogen anti-lingo drug candid key part
ms pipelin drug could help repair myelin
sheath coat neuron give novel mechan
action potenti allow patient regain lost
function drug fail hit key endpoint
phase studi saw encourag data
clinic respons opicinumab continu move forward
develop oncolog expect partner
subcutan rituxan also next-gener drug
gazyva launch leukemia indol
first-lin lymphoma product superior efficaci
profil rituxan
extend oncolog profit stream
individu odd approv mix bullish
novel broader neurolog rare-diseas
pipelin includ sever product high risk
spinraza launch annual price
lack treatment option rare deadli diseas
could creat billion market although
assum sale could peak around billion
spinraza begin share market novarti gene
therapi zolgensma divers pipelin follow
spinraza area includ ms novel re-myelin
therapi opicinumab pain vixotrigin stroke
parkinson al
follow mix data aducanumab
program alzheim model probabl
approv explicitli model firm amyloid
fail trial supranuclear palsi drug well
two tau-target therapi neurimmun
ioni develop alzheim give
exposur potenti new target diseas none
explicit forecast
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
lead billion global ms market
avonex plegridi tysabri tecfidera
launch vumer could help protect tecfidera
franchis gener competit
receiv royalti profit share roch
ms drug ocrevu cancer therapi rituxan
neurolog portfolio outsid ms includ
spinraza therapi sever neurolog
diseas includ parkinson al alzheim
help diversifi revenu boost sale growth
oinject ms therapi like avonex lost
edg brand oral competit gener
inject launch tysabri risk profil
make vulner patient switch roch
aducanumab halt march although
firm plan file approv launch far
certain demonstr high-risk natur
drive growth oral
competit roche/ptc gene therapi novarti
could threaten franchis beyond
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
year-end cash balanc billion free
cash flow billion annual help fund
futur repurchas allow firm flexibl size
futur acquisit firm cash invest
balanc sheet match similar amount debt
matur issu billion
debt help fund share-repurchas program
histor focus return excess cash
sharehold via buyback limit acquisit
collabor record strong expect tuck-in
acquisit go forward billion free cash
flow gener spent vast
major cash repurchas averag
repurchas price per share
profit depend four key blockbust
high-risk potenti high-reward pipelin
physician payer fail support gazyva use
rituxan despit strong superior data leukemia
larg lymphoma set roch could
vulner competit cheaper biosimilar rituxan
 revenu roch
collabor feed directli bottom line boost
margin plegridi like help
maintain lead interferon market expect gener
copaxon weigh sale inject ms therapi
ms portfolio enjoy tremend price
power unit state insur could begin find
way put pressur futur price increas
competitor reach market avonex plegridi
exclud nation formulari
tecfidera sale see slower growth partli due
concern case pml gastrointestin issu
oral drug celgen ozanimod pois
enter market mix result alzheim therapi
aducanumab phase trial also demonstr
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
high-risk natur chosen area focu
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
repres date owner name posit common share held report holder issuer
capit research manag compani
share
fund
share
fund
scango took ceo juli longtim
execut jame mullen serv ceo
development-stag biotech year
previous spend year bayer scango help
refocu pipelin neurodegen diseas
neurology-rel indic build strong team
neurolog drug discoveri emphas small tuck-in
commerci offic toni kingsley chief doug
left scango depart
begin decis spin firm
hemophilia franchis led specul firm
sale despit turnov chief medic offic alfr
sandrock decad experi support
pipelin recent ad titl execut vice
presid departur michael ehler
chief commerci offic career
longtim director william young step
role independ chairman replac stelio
papadopoulo chairman regulu
annual meet may overal see
board well qualifi divers independ despit
long tenur sever director applaud
effort emphas restrict stock option
compens packag top execut
believ align interest sharehold howev
take-over defens author prefer stock may
work interest sharehold complex right
agreement partner roch
trigger acquir could damp
enthusiasm potenti acquir
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
coronaviru affect drug firm moat
slightli lower pharma
fair valu estim almost aggreg much less
stock declin result disrupt
caus coronaviru outbreak high need drug
support continu demand suppli also
expect new treatment vaccin reduc long-
term impact viru expect chang
moat rate innov continu minor
disrupt success coronaviru treatment
pharmaceut industri also remind world
social import group key esg factor
industri shield potenti pressur
look bigger pictur around coronaviru
challeng view four key point drug biotech
industri first expect much impact drug sale
econom disrupt coronaviru caus
drug demand tend highli inelast
govern like priorit drug suppli second
drug util near term like face disrupt
especi new drug drug new indic
expect entrench drug face minor
impact third beyond capit appreci view
dividend group secur averag pay-out
ratio close give firm room adapt near-
term coronaviru pressur last expect new medicin
vaccin emerg treat coronaviru limit
background outlook coronaviru
impact pharma industri
pleas see report titl coronaviru caus limit
impact pharma moat valuat
dividend look attract market pullback
defens natur healthcar firm offer
concern around global recess due coronaviru
disrupt weigh global market
defens natur healthcar hold rel
basi dont expect signific chang
healthcar moat rate may make downward
adjust valuat healthcar account
near-term challeng expect modest chang
rel recent stock price movement base case
call strong econom rebound follow
recess modest impact
healthcar valuat given defens natur
compani howev coronaviru pandem exert
sustain impact economi significantli higher
number patient unemploy uninsur
underinsur could reduc healthcar demand
greater extent expect govern effort reduc
near-term hit keep harder-hit industri
busi effect treatment emerg
near-term effect coronaviru expect critic
therapi crowd elect procedur new
product non-critical-car product fewer elect
procedur weigh devic maker servic
focus covid-specif case could reduc
profit health insur brand drug firm
alreadi focus specialti drug expect less impact
industri drug administ hospit could
still feel crowd coronaviru patient also
clinic develop timelin probabl face
delay due coronaviru disrupt like slow
new product launch addit coronaviru
impact credit market could weigh heavili
indebt compani hospit firm
compani recent complet major acquisit
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
outlook coronaviru global
economi well potenti new treatment
coronaviru pleas see
widespread diseas drug pipelin progress
outlook chang drug price polici
initi result super tuesday democrat primari
show increas support former vice presid biden
whose nomin would reduc likelihood signific
drug price polici chang line
expect dont expect major chang fair
valu estim moat rate drug biotech
industri base result continu view
industri under-valued averag
due partli excess concern around potenti major
drug polici chang note elect result
bigger impact healthcar insur servic
relief ralli health insur servic provid
drug side movement toward moder
democrat biden like mean minor drug polici
chang reduc chanc medicar
scenario champion biden key oppon sen
berni sander would like significantli reduc
drug price negoti power one-pay
system elect support shift toward biden
believ like chang drug price polici
reform center around senat bill prescript drug
price reduct act pdpra howev still believ
propos hold less chanc pass base
mix level support parti havent
includ passag bill model howev
pass estim aggreg hit brand
drug sale medicar inflat price cap part
redesign propos bill believ drug
biotech industri could adapt headwind
minor impact cash flow partli cost cut
increas volum base lower price mandat
bill importantli bill would limit out-of-pocket
payment patient medicar would like help
appeas demand lower drug price
potenti drug polici chang key element
esg analysi drug firm pleas see recent
healthcar observ esg risk affect moat
pharma morningstar
patent trial appeal board rule favor
valid key patent multipl sclerosi drug
tecfidera increas fair valu estim
per share rais tecfidera sale
estim year expect potenti
gener competit beyond petit inter
part review file process
attempt strip formul patent protect
tecfidera given patent histori think
solid support tecfidera prospect also
prevail previou inter part review patent
file coalit afford drug
interfer proceed forward pharma
file sever patent infring case
would-b gener competitor expect
decis abil protect
revenu stream significantli strengthen key
patent valid tecfidera lend addit
support firm wide moat alreadi view
stabl due profit share ms drug ocrevu
howev remain cautiou attempt
extend franchis vumer although
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
less critic given patent expir
vumer
gastrointestin toler benefit tecfidera
clinic meaning think drug receiv
 food drug administr approv octob
see littl traction competit marketplac
signific profit share sale ocrevu much
bigger driver valuat inform
ms market dynam see innov multipl
sclerosi support moat roch ocrevu still look
fve assum tecfidera gener jan
report stronger revenu earn growth
fourth quarter model lead top-
line non-gaap ep growth full year
guidanc billion sale
non-gaap ep
forecast firm seen strong retent sale
older multipl sclerosi drug despit competit
also benefit royalti stream roch
billion ms therapi ocrevu continu grow
strongli allow total ms revenu growth
year spinal muscular atrophi slightli
rais spinraza assumpt although
continu think sale declin start year due
competit novarti zolgensma among infant
drug million sale fourth quarter
quickli ramp approach spinraza quarterli sale
albeit much higher price point roch oral drug
risdiplam among older patient risdiplam could approv
 may also ad program
lupu drug biosimilar version ophthalmolog
drug eylea lucenti model follow posit
phase data biosimilar drug licens
samsung decemb partli counter
boost assumpt sg expens higher
spend ahead potenti aducanumab launch
alzheim later year well tax rate
overal maintain fair valu estim
firm see firm ocrevu profit share
pressur spinraza tecfidera
week could bring import catalyst
ms drug tecfidera decis inter part review
key patent releas patent infring case
also decis biogen
would appeal neg rule current assum
tecfidera gener enter market also
despit belief vumer gastrointestin
toler benefit tecfidera clinic meaning
think drug receiv fda approv
octob see littl traction competit marketplac
inform ms market dynam pleas see
report innov multipl sclerosi support
moat roch ocrevu still look underappreci
esg perspect multipl sclerosi
portfolio built largest price
discrep versu develop market high
exposur market make vulner futur
price risk one key social risk model howev
current valuat appear give enough credit
newer product pipelin detail
esg analysi pleas see report esg risk
affect moat valuat pharma
sustainalyt offer complementari
pipelin potenti clearli led aducanumab
sever program pois produc data
next two year data novel ms drug
ophthalmolog gene therapi timrepigen
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
emparvovec could drive bullish sentiment
continu model probabl weight sale
probabl approv billion aducanumab
assum potenti approv later year think
opicinumab cinpanemab ophthalmolog
gene therapi program capabl reach sale
north billion approv see lower chanc
approv ms parkinson program due high
risk/high-reward natur program
sustainalyt esg risk methodolog
point opportun pharma/biotech jan
sustainalyt
own
collabor broaden deepen
esg analysi incorpor environment social
govern factor valuat analysi
pharma focus
materi esg issu social realm think
firm expos esg risk morningstar
conclud valuation-affect esg risk brand
drug firm center price risk larg litig
provid comprehens evalu support
mostli wide moat rate industri
also like sanofi
valuat esg risk johnson johnson eli lilli look
least compel us base litig risk
valuat look under-valued
detail analysi price litig issu
top pharma name
coverag see januari
healthcar observ esg risk affect moat
pharma morningstar
trump propos drug reimport look limit
potenti lower drug price dec
trump administr move allow drug import
canada look challeng implement
limit scope dont expect major chang
fair valu estim drug biotechnolog
industri view administr move driven
polit motiv anoth elect cycl draw
near rather major structur shift influenc drug
price continu view price power drug
strong central pillar support moat rate
larg drug biotechnolog compani
overal see under-valued name roch
biomarin lowest exposur esg-rel
strategi focu sever diseas lower price
pressur includ base case alreadi factor much
potenti headwind intern benchmark
price could test medicar part
biomarin global price strategi rare-diseas drug
well seriou natur condit limit futur
price litig risk despit high price tag
medicar exposur minim
import action propos
human servic juli propos rule
releas fda decemb dont view
plan major driver lower drug price think
implement chang would difficult
practic hard reconcil safeti provis
part feder track-and-trac system stop
counterfeit drug ensur enough drug-firm suppli low
price canada anoth concern drug firm could
limit distribut limit re-import also canada would
like support plan low drug price would
like face rise pressur support price
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
implement scope drug target potenti
re-import limit exclud drug biolog
inject drug drug subject fda risk evalu
mitig strategi rem drug group repres
core area focu new drug reach market
congress support drug re-import past
safe implement propos limit
enact expect similar limit around
recent propos given complex distribut
differ drug label countri see poor
prospect wide use drug re-import
background polici propos
enact pleas see healthcar observ drug
price reform weigh valuat moat look
secur biotech industri look under-valued within
report highlight impact enact chang
drug payment increas discount
medicar part doughnut hole sale also review
depth drug polici propos council
econom advisor budget
rais fair valu estim follow
present addit phase data alzheim
diseas drug candid aducanumab clinic trial
alzheim diseas meet dec
slightli rais fair valu estim
follow view reassur detail still
plan file food drug administr approv
aducanumab earli base full data two
phase studi engag emerg slightli
increas assum probabl approv
aducanumab incorpor sale
nearli billion nearli billion approv year
model today updat encourag
still uncertain whether fda see weaker
engag trial confirmatori benefit seen
emerg studi continu award wide moat
rate base stabil multipl sclerosi
franchis diversif neurolog spinraza
solid neurolog pipelin although highlight high
uncertainti come innov high-risk
background discuss oct note
aducanumab develop stop march
futil analysi pool data two trial indic
less probabl meet primari
endpoint howev time alreadi
indic emerg studi trend posit
engag fulli realiz extent
impact protocol amend result
trial disclos octob addit data
patient allow aducanumab meet primari
high-dos patient emerg studi engag studi
enrol earlier emerg
affect
amend push patient toward lower dose
still meet endpoint analysi engag studi
subset patient receiv high uninterrupt
dose drug patient sometim suspend treatment
due side effect seem impli similar efficaci
emerg although statist around data
sever unknown around analysi led mix
respons investor alzheim expert
treatment protocol use
final full data set reveal almost ident data
larger data set reveal octob slower
declin cdr-sb diseas sever metric high-dos
patient placebo emerg faster declin
placebo engag one key question go
dec present whether one-month
differ trial start date engag emerg
big enough protocol amend allow patient
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
carri genet risk take high
dose could prevent advanc engag
studi meet endpoint disclos
amend made march engag
patient enrol emerg result
fewer carrier patient receiv high dose result
patient receiv possibl treatment
engag studi versu emerg studi
perhap importantli provid help
analysi patient enrol amend
compar patient high-dos low-dos arm
studi placebo patient among high-dos
patient emerg engag receiv
possibl dose creat less differ total
dose analysi reveal reduct declin
cdr-sb emerg reduct declin cdr-
sb engag high-dos patient think show
consist trial could enough
support approv howev full
month data would trial
complet well signific dose interrupt
prevent clear data long-term benefit
patient even redos fda could requir anoth
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
